JPWO2020132504A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132504A5 JPWO2020132504A5 JP2021535679A JP2021535679A JPWO2020132504A5 JP WO2020132504 A5 JPWO2020132504 A5 JP WO2020132504A5 JP 2021535679 A JP2021535679 A JP 2021535679A JP 2021535679 A JP2021535679 A JP 2021535679A JP WO2020132504 A5 JPWO2020132504 A5 JP WO2020132504A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- independently hydrogen
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094279A JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784222P | 2018-12-21 | 2018-12-21 | |
| US201862784229P | 2018-12-21 | 2018-12-21 | |
| US62/784,222 | 2018-12-21 | ||
| US62/784,229 | 2018-12-21 | ||
| PCT/US2019/067953 WO2020132504A1 (en) | 2018-12-21 | 2019-12-20 | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094279A Division JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022514385A JP2022514385A (ja) | 2022-02-10 |
| JP2022514385A5 JP2022514385A5 (https=) | 2022-11-18 |
| JPWO2020132504A5 true JPWO2020132504A5 (https=) | 2022-11-18 |
| JP7692830B2 JP7692830B2 (ja) | 2025-06-16 |
Family
ID=69591712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535679A Active JP7692830B2 (ja) | 2018-12-21 | 2019-12-20 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
| JP2024094279A Pending JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094279A Pending JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220372067A1 (https=) |
| EP (1) | EP3898646B1 (https=) |
| JP (2) | JP7692830B2 (https=) |
| KR (1) | KR20210107050A (https=) |
| CN (1) | CN113195512A (https=) |
| AU (2) | AU2019403415B2 (https=) |
| BR (1) | BR112021012242A2 (https=) |
| CA (1) | CA3124371A1 (https=) |
| IL (1) | IL284183A (https=) |
| MX (2) | MX2021007504A (https=) |
| TW (2) | TWI848034B (https=) |
| WO (1) | WO2020132504A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| IL283629B2 (en) | 2018-12-05 | 2026-03-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN113195512A (zh) * | 2018-12-21 | 2021-07-30 | 萨奇治疗股份有限公司 | 3.α.-羟基-17.β.-酰胺神经活性类固醇及其组合物 |
| IL299176A (en) * | 2020-06-24 | 2023-02-01 | Sage Therapeutics Inc | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| CN119192275B (zh) * | 2024-08-22 | 2025-05-30 | 湖南玉新药业有限公司 | 一种3-羰基-4-氮杂-5α-雄甾-17β-羧酸化合物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CN119192266A (zh) | 2011-10-14 | 2024-12-27 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| US9512170B2 (en) * | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| EP4155314A1 (en) * | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| IL283629B2 (en) * | 2018-12-05 | 2026-03-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN113195512A (zh) * | 2018-12-21 | 2021-07-30 | 萨奇治疗股份有限公司 | 3.α.-羟基-17.β.-酰胺神经活性类固醇及其组合物 |
-
2019
- 2019-12-20 CN CN201980085054.3A patent/CN113195512A/zh active Pending
- 2019-12-20 US US17/416,367 patent/US20220372067A1/en active Pending
- 2019-12-20 TW TW108147086A patent/TWI848034B/zh active
- 2019-12-20 CA CA3124371A patent/CA3124371A1/en active Pending
- 2019-12-20 KR KR1020217022533A patent/KR20210107050A/ko not_active Ceased
- 2019-12-20 AU AU2019403415A patent/AU2019403415B2/en active Active
- 2019-12-20 WO PCT/US2019/067953 patent/WO2020132504A1/en not_active Ceased
- 2019-12-20 MX MX2021007504A patent/MX2021007504A/es unknown
- 2019-12-20 TW TW113121961A patent/TWI892697B/zh active
- 2019-12-20 EP EP19850836.8A patent/EP3898646B1/en active Active
- 2019-12-20 JP JP2021535679A patent/JP7692830B2/ja active Active
- 2019-12-20 BR BR112021012242-7A patent/BR112021012242A2/pt unknown
-
2021
- 2021-06-18 MX MX2025000126A patent/MX2025000126A/es unknown
- 2021-06-20 IL IL284183A patent/IL284183A/en unknown
-
2024
- 2024-06-11 JP JP2024094279A patent/JP2024107296A/ja active Pending
-
2025
- 2025-11-13 AU AU2025267433A patent/AU2025267433A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534124A5 (https=) | ||
| CN101142198B (zh) | 用于治疗疾病的异*唑坎布雷它斯丁衍生物 | |
| ES2399241T3 (es) | Compuestos de triazol que modulan la actividad de HSP90 | |
| JP5523839B2 (ja) | 癌などの増殖障害の治療に有用なトリアゾール化合物 | |
| KR101942151B1 (ko) | Hbv 감염에 대한 항바이러스 물질 | |
| JP5178515B2 (ja) | Ｈｓｐ９０活性を調節するピラゾール化合物 | |
| JP2002524463A5 (https=) | ||
| JP2023119042A5 (https=) | ||
| JP5118039B2 (ja) | Ｈｓｐ９０活性を調節するトリアゾール化合物 | |
| JPWO2020132504A5 (https=) | ||
| US20030045518A1 (en) | Taxol enhancer compounds | |
| JP2021527638A5 (https=) | ||
| RU2012107101A (ru) | Производные пирроло[1,2-в] пиридазина как ингибиторы янус-киназы | |
| JP2021514001A5 (https=) | ||
| BR112020008833A2 (pt) | moduladores da via de estresse integrada | |
| JPWO2022177917A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2014500322A5 (https=) | ||
| JP2017505793A (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| JPWO2020118060A5 (https=) | ||
| JP2004525183A5 (https=) | ||
| JPWO2019140272A5 (https=) | ||
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JPWO2020264512A5 (https=) | ||
| JPWO2021262836A5 (https=) |